The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Pacific Biosciences of California Inc.’s current trading price is -36.01% away from its 52-week high, while its distance from the 52-week low is 87.32%. The stock’s price range for this period has been between $4.97 and $14.55 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 2.04 million for the day, a number notably lower than the average daily volume of 3.58 million over the last three months.
At present, Pacific Biosciences of California Inc. (PACB) has a stock price of $9.31. In the previous session, the stock saw a rise, peaking at $10.37 after an opening price of $10.37. The day’s lowest price was $9.565, and it closed at $9.68.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
The market performance of Pacific Biosciences of California Inc.’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point at $14.55 on 07/18/23, while the lowest value for the same duration was $4.97 on 09/29/22.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Pacific Biosciences of California Inc. (PACB) has experienced a quarterly decline of -28.99% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.46B and boasts a workforce of 769 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 12.18, with a change in price of -0.70. Similarly, Pacific Biosciences of California Inc. recorded 3,665,971 in trading volume during the last 100 days, posting a change of -7.02%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for PACB stands at 1.39. Similarly, the long-term debt-to-equity ratio is also 1.39.
PACB Stock Stochastic Average
As of today, Pacific Biosciences of California Inc.’s raw stochastic average for the last 50 days stands at 2.13%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 4.11%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 12.89% and 33.97%, respectively.
PACB Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. Year to date metric has recorded a gain of 13.81%.However, over the last six months, we can see a weaker performance of 11.36%. Over the last 30 days, the price of PACB has leaped by -10.14%. And in the last five days, it has fallen by -13.48%.
